Waldenstrom's macroglobulinemia: Recent advances in biology and therapy

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 10, 2009, Pages 677-690

  Neparidze, Natalia ^a   Dhodapkar, Madhav V ^b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Macroglobulinemia; Pathogenesis; Review; Therapy

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ALEMTUZUMAB; ALKYLATING AGENT; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BENDAMUSTINE; BORTEZOMIB; C REACTIVE PROTEIN; CD27 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN M; INTERLEUKIN 6; LENALIDOMIDE; NUCLEOSIDE ANALOG; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN CDC42; PROTEIN P62; RAB PROTEIN; RHO FACTOR; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE;

ANEMIA; B LYMPHOCYTE; BLOOD ANALYSIS; BLOOD VISCOSITY; BONE MARROW BIOPSY; CANCER REGRESSION; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 6Q; CHROMOSOME DELETION; CLINICAL TRIAL; CYTOPENIA; FEBRILE NEUTROPENIA; GENE MUTATION; GENE REARRANGEMENT; HEMOLYSIS; HUMAN; INFECTION; LYMPHOCYTIC INFILTRATION; MEDICAL DECISION MAKING; MONOCLONAL IMMUNOGLOBULINEMIA; NEUROPATHY; NEUTROPENIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PROGNOSIS; REVIEW; SOMATIC HYPERMUTATION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UPREGULATION; WALDENSTROEM MACROGLOBULINEMIA; WATCHFUL WAITING;

HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 70449640615     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Waldenstrom J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia-a new syndrome? Acta Med Scand. 1944;117:216-247.
2. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood. 1993;82:3148-3150.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
4. McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:146-152.
5. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol. 2003;30:169-171. (Pubitemid 36506303)
6. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clono-typic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood. 2004;104:2134-2142. (Pubitemid 39297868)
7. Babbage G, Townsend M, Zojer N, et al. IgM-expressing Waldenstrom's macroglobulinemia tumor cells reveal a potential for isotype switch events in vivo. Leukemia. 2007;21:827-830. (Pubitemid 46444577)
8. Martin-Jimenez P, Garcia-Sanz R, Sarasquete ME, et al. Functional class switch recombination may occur 'in vivo' in Waldenstrom macroglobulinaemia. Br J Haematol. 2007;136:114-116.
9. Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136:80-86.
10. Chang H, Samiee S, Li D, Patterson B, Chen CI, Stewart AK. Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 cases. Leukemia. 2004;18:1160-1162.
11. Schop RF, Jalal SM, Van Wier SA, et al. Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet. 2002;132:55-60.
12. Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108:2755-2763.
13. Hatzimichael EC, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia. Eur J Haematol. 2001;66:1-6.
14. Gutierrez NC, Ocio EM, Rivas JDL, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia. 2007;21:541-549.
15. Pascal L, Gay J, Willekens C, et al. Bortezomib and Waldenstrom's macroglobulinemia. Expert Opin Pharmacother. 2009;10:909-916.
16. Hatjiharissi E, Ngo H, Leontovich AA, et al. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007;67:3777-3784.
17. Sahota SS, Babbage G, Weston-Bell NJ. CD27 in defining memory B-cell origins in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9: 33-35.
18. Fonseca R, Hayman S. Waldenstrom macroglobulinaemia. Br J Haematol. 2007;138:700-720.
19. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98:41-48.
20. Elsawa SF, Novak AJ, Grote DM, et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood. 2006;107:2882-2888.
21. Ho AW, Hatjiharissi E, Ciccarelli BT, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008;112:4683-4689.
22. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110-115.
23. Bain BJ. Dutcher bodies. Am J Hematol. 2009;84:589.
24. Owen RG. Developing diagnostic criteria in Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:196-200.
25. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163-4170.
26. Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood. 2009;113:793-796.
27. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:116-120.
28. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009;23:1545-1556
29. Leleu X, Gay J, Roccaro AM, et al. Update on therapeutic options in Waldenstrom macroglobulinemia. European Journal of Haematology. 2009;82:1-12.
30. Leleu X, Gay J, Roccaro AM, et al. Update on therapeutic options in Waldenstrom macroglobulinemia. Eur J Haematol. 2009;82:1-12.
31. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med. 1993;95:49-52.
32. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:243-247.
33. Tedeschi A, Miqueleiz S, Ricci F, et al. Fludarabine, cyclophosphamide and rituximab in Waldenstrom's macroglobulinemia: An effective regimen requiring a new category of response criteria and a delayed assessment of results. Blood. 2007;110:388a-388a.
34. Vargaftig J, Pegourie-Bandelier B, Mahe B, et al. Fludarabine plus cyclo-phosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM): Results in 25 patients. Haematol-Hematol J. 2007;92:227-227
35. Leleu X, Manning R, Soumerai J, et al. Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogs. Haematol-Hematol J. 2007;92: 95-96.
36. Leleu X, Tamburini J, Roccaro A, et al. Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analogue- based therapy. Clin Lymphoma Myeloma. 2009;9:71-73.
37. Leblond V, Levy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001;98:2640-2644.
38. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344-3349.
39. Abonour R, Zhang LA, Rajkumar V, et al. Phase II pilot study of rituximab plus CHOP in patients with newly diagnosed Waldenstrom's macroglobulinemia, an eastren cooperative oncology group trial (Study E1A02). Blood. 2007;110:1058a-1058a.
40. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:62-66.
41. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
42. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248. Clin Cancer Res. 2007;13:3320-3325. (Pubitemid 46944918)
43. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1570-1575. (Pubitemid 46733084)
44. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. J Clin Oncol. 2009;27:3830-3835.
45. Agathocleous A, Rule S, Johnson P, et al. Preliminary results of a phase I/ II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom's macroglobulinaemia. Blood. 2007;110:754a-754a.
46. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology. 2006;24:2105-2112. (Pubitemid 46622122)
47. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112:4452-4457.
48. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and Rituximab in Waidenstrom's Macroglobulinemia. Clinical Cancer Research. 2009;15:355-360.
49. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27:120-126.
50. Hunter ZR, Boxer M, Kahl B, et al. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079. J Clin Oncol. 2006;24:427s-427s.
51. Ghobrial IM, Leleu X, Rubin N, et al. Phase II trial of perifosine (KRX- 0401) in relapsed and/or refractory Waldenstrom macroglobulinemia: Preliminary results. Blood. 2007;110:194b-195b.
52. Soumerai J, O'Connor K, Ioakimidis L. Imatinib mesylate (Gleevec) produces responses in patients with relapsed/refractory Waldenstroms macroglobulinemia. Blood. 2007;110:2575.
53. Gertz MA, Geyer SM, Badros A, Kahl BS, Erlichman C. Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005;5:282-284. (Pubitemid 40614244)
54. Rossi J, Moreaux J, Rose M, et al. Phase I/II study of Atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple or active previously treated Waldenstrom's macroglobulinemia. Blood. 2006;108:3578.
55. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45:2047-2055. (Pubitemid 39232853)
56. Dimopoulos M, Kantarjian H, Weber D. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994;12:2694-2698. (Pubitemid 24379658)
57. Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia. 2005;19:1831-1834. (Pubitemid 41486163)
58. Treon SP, Soumerai JD, Hunter ZR, et al. Novel agents in the treatment of Waldenstrom's macroglobulinemia: Update of WMCTG clinical trials. Haematologica-the Hematology Journal. 2007;92:91-91